Composition for the treatment of atopic dermatitis comprising Bifidobacterium animalis subsp. lactis LM1017

#This application claims the benefit under 35 USC 119(a) of Korean Patent Application No. 10-2019-0173156 filed on Dec. 23, 2019 in the Korean Intellectual Property Office, the entire disclosure of which is incorporated herein by reference for all purposes.

#The present disclosure relates to a composition for the prevention and treatment of atopic dermatitis, containing Bifidobacterium animalis subsp. lactis LM1017 and more particularly, to a composition for the prevention and treatment of atopic dermatitis, containing Bifidobacterium animalis subsp. lactis LM1017 that inhibits the expression level and inflammatory response of inflammatory cytokines by regulating an NF-κB signaling pathway.

#Dermatitis refers to histological phenomena such as spongiosis of the epidermis, infiltration of inflammatory cells, vascular proliferation and vasodilation in the hypodermis, and infiltration of perivascular inflammatory cells. Dermatitis is classified into atopic dermatitis, contact dermatitis and seborrheic dermatitis, and people with dermatitis may suffer from pain caused by itching, erythema, swelling, and oozing and also suffer from emotional distress caused by the gaze of others, which results in difficulty in social adaptation.

#FIG. 1 is a graph showing the cell viability of RAW 264.7 cells with Bifidobacterium animalis subsp. lactis LM1017 [Depository Institution: Korean Culture Center of Microorganisms (KCCM), Accession Number: KCCM12629P, and Date of Deposit: Nov. 14, 2019] according to an example of the present disclosure.

#FIG. 2A and FIG. 2B are graphs showing the effect of regulating the expression levels of IL-6 and IL-1β mRNA by Bifidobacterium animalis subsp. lactis LM1017 according to an example of the present disclosure in RAW 264.7 cells and inflammation induced RAW 264.7 cells with LPS.

#FIG. 3A to FIG. 3C are graphs showing the effect of regulating the expression levels of p65, IκB-α, and p-IκB-α by Bifidobacterium animalis subsp. lactis LM1017 according to an example of the present disclosure in RAW 264.7 cells and inflammation induced RAW 264.7 cells with LPS, and FIG. 3D illustrates a correlation between Bifidobacterium animalis subsp. lactis LM1017 and an NF-κB signaling pathway.

#Hereafter, examples of the present disclosure will be described in detail with reference to the accompanying drawings so that the present disclosure may be readily implemented by a person with ordinary skill in the art. However, it is to be noted that the present disclosure is not limited to the examples but can be embodied in various other ways. In the drawings, parts irrelevant to the description are omitted for the simplicity of explanation, and like reference numerals denote like parts through the whole document.

#Throughout this document, the term “connected to” may be used to designate a connection or coupling of one element to another element and includes both an element being “directly connected to” another element and an element being “electronically connected to” another element via another element.

#Through the whole document, the term “on” that is used to designate a position of one element with respect to another element includes both a case that the one element is adjacent to the other element and a case that any other element exists between these two elements.